RT Journal Article
SR Electronic
T1 Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20106856
DO 10.1101/2020.05.19.20106856
A1 Dambha-Miller, Hajira
A1 Albasri, Ali
A1 Hodgson, Sam
A1 Wilcox, Christopher R
A1 Khan, Shareen
A1 Islam, Nazrul
A1 Little, Paul
A1 Griffin, Simon J
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106856.abstract
AB Objective To review evidence on routinely prescribed drugs in the UK that could up or downregulate Angiotensin Converting Enzyme 2 (ACE2) and potentially affect COVID-19 diseaseDesign Systematic reviewData source MEDLINE, EMBASE, CINAHL, the Cochrane Library and Web of ScienceStudy selection Any design with animal or human models examining a currently prescribed UK drug compared to a control, placebo or sham group, and reporting an effect on ACE2 level, activity or gene expression.Data extraction and synthesis MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science and OpenGrey from inception to 1st April 2020. Methodological quality was assessed using the SYRCLE’s risk of bias tool for animal studies and Cochrane risk of bias tool for human studies.Results We screened 3,360 titles and included 112 studies with 21 different drug classes identified as influencing ACE2 activity. Ten studies were in humans and 102 were in animal models None examined ACE2 in human lungs. The most frequently examined drugs were Angiotensin Receptor Blockers (ARBs) (n= 55) and Angiotensin-Converting Enzyme-Inhibitors (ACE-I) (n= 22). More studies reported upregulation than downregulation with ACE-I (n=22), ARBs (n=55), insulin (n=8), thiazolidinedione (n=7) aldosterone agonists (n=3), statins (n=5), oestrogens (n=5) calcium channel-blockers (n=3) GLP-1 agonists (n=2) and NSAIDs (n=2).Conclusions There is an abundance of academic literature and media reports on the potential of drugs that could attenuate or exacerbate COVID-19 disease. This is leading to trials of repurposed drugs and uncertainty amongst patients and clinicians concerning continuation or cessation of prescribed medications. Our review indicates that the impact of currently prescribed drugs on ACE2 has been poorly studied in-vivo, particularly in human lungs where the SARS-CoV-2 virus appears to enact its pathogenic effects. We found no convincing evidence to justify starting or stopping currently prescribed drugs to influence outcomes of COVID-19 disease.Strengths and limitationsThis review addresses a high priority patient and clinician concernGiven the limited evidence on the subject, we included human and animal models both in vivo and in vitro for a comprehensive reviewThis is the first systematic review specifically focussed on UK prescribed drugs that could alter ACE2 in COVID-19 diseaseThe heterogeneity across study designs and models meant meta-analysis was not suitableGiven the rapidly changing evidence as the pandemic progresses, it is possible that new studies have since been published.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Southampton, Cambridge and Oxford Primary Care Departments are members of the NIHR School for Primary Care Research and supported by NIHR Research funds. The University of Cambridge has received salary support in respect of SJG from the NHS in the East of England through the Clinical Academic Reserve. SJG is supported by an MRC Epidemiology Unit programme: MC_UU_12015/4. HDM is an NIHR Clinical Lecturer and supported by an NIHR SPCR grant for this work: SPCR2014-10043. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable from authors with reasonable request